With the number of Americans living with the disease steadily increasing, scientists predict that 13.8 million will have Alzheimer’s by 2050, or 16% of the US population over the age of 65 ...

A lzheimer’s disease is characterized by the accumulation of amyloid β (Aβ) peptides and the protein Tau in neurons in the brain. As a result, researchers focused on the central nervous system to ...

A new study links cold sores to Alzheimer's, highlighting HSV-1's role. Women in particular could have a higher risk. Anti-herpetic drugs may reduce dementia chances.

The FDA greenlit marketing for the first blood test to help diagnose Alzheimer’s disease. Experts believe this will increase access to Alzheimer’s detection and reduce reliance on expensive ...

Across 344,628 Alzheimer's case-control pairs, a history of HSV-1 diagnosis was present in 1,507 people (0.44%) with Alzheimer's disease and 823 matched controls (0.24%), reported Yunhao Liu, PhD ...

UCLA researchers have developed a drug that counteracts the impaired cognition caused by Alzheimer’s disease and reestablishes brain connections following strokes in mice. The team began ...

A blood test that can help diagnose Alzheimer’s disease has received clearance from the Food and Drug Administration. This is a step toward a goal of scientists and doctors to one day be able to ...

"I lost my mother to Alzheimer's disease." Most efforts to treat Alzheimer's involve clearing the brain of the disease's hallmarks: sticky amyloid plaques and tangled fibers called tau.

Inhibiting 15-PGDH blocks blood–brain barrier deterioration and protects mice from Alzheimer’s disease and traumatic brain injury. Proceedings of the National Academy of Sciences , 2025; 122 ...

Alzheimer’s disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and ...

INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares ...